Key Development
Swiss generic and biosimilar leader Sandoz (SIX: SDZ / OTCQX: SDZNY) has entered into a major commercial licensing agreement with Chinese biopharmaceutical company Shanghai Henlius Biotech (HKEX: 2696). The agreement represents a total potential consideration of up to $322 million, comprising $100.5 million in upfront payments alongside contingent development, regulatory, and commercial milestone commitments.
The transaction secures Sandoz exclusive commercialization rights outside Greater China for three early-stage biosimilar assets, while establishing a framework to collaborate on up to 10 biosimilar candidates over time.
Targeted Blockbuster Originator Assets:
-
Biosimilar Repatha® (evolocumab – Amgen): Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor for hypercholesterolemia, generating $3.0 billion in global sales in 2025 (+36% YoY growth).
-
Biosimilar Benlysta® (belimumab – GSK): B-lymphocyte stimulator (BLyS) inhibitor indicated for systemic lupus erythematosus (SLE).
-
Biosimilar Erbitux® (cetuximab – Eli Lilly / Merck KGaA): Epidermal growth factor receptor (EGFR) inhibitor indicated for metastatic colorectal cancer and head and neck cancer.
(The three reference blockbusters generated combined global sales of $6.8 billion in 2025).
Operational Allocation & Portfolio Scope:
-
Shanghai Henlius: Retains clinical development and commercial manufacturing responsibilities, alongside exclusive commercial rights across Mainland China.
-
Sandoz: Directs regulatory filings, commercial launch, and marketing across all territories outside China (North America, Europe, Latin America, APAC ex-China).
-
Expanding Global Biosimilar Leadership: The addition expands Sandoz’s pipeline to 39 biosimilars, with the option to expand to 46 programs if all expansion assets are integrated.
Why It Matters
-
Capitalizing on the Upcoming “Loss-of-Exclusivity (LOE) Wave”: A substantial wave of biologic patent expirations scheduled across 2026–2035 creates a multibillion-dollar commercial opportunity. In-licensing early-stage programs allows Sandoz to maintain pipeline momentum.
-
Unlocking High-Barrier Off-Patent Molecules (Erbitux®): While Erbitux® lost primary patent exclusivity a decade ago, molecular complexity and analytical hurdles deterred market entrants. Henlius’s validated clone provides Sandoz with an early entry point in this niche oncology market.
-
Expanding Strategic Synergy with Henlius: In April 2025, Sandoz executed a licensing pact paying $31 million upfront and $270 million in milestones for Henlius’s biosimilar version of Bristol Myers Squibb’s CTLA-4 inhibitor Yervoy® (ipilimumab, $2.9B in 2025 sales).
-
Accelerating Biosimilar Revenue Mix: Sandoz reported $11.1 billion in total 2025 revenue, with biosimilars contributing $3.3 billion (+13% YoY), achieving its 30% revenue share target three years ahead of strategic projections. The company is advancing plans to establish a standalone biosimilars operating unit.
Healthcare Insight Analysis
From the perspective of Healthcare Insight, the $322 million transaction between Sandoz and Shanghai Henlius on August 17, 2026, illustrates Cross-Border Biosimilar Arbitrage Strategy.
Following its corporate spinoff from Novartis, Sandoz is executing a three-pillar biosimilar expansion strategy:
-
R&D Cost Optimization via In-Licensing: Rather than funding internal early-stage cell-line development in Western facilities, Sandoz utilizes Henlius’s bioprocessing infrastructure in Shanghai, reducing capital intensity while accelerating development cycle times.
-
Targeting High-Barrier Biologics Over Saturated Classes: By selecting PCSK9 and complex EGFR mAbs rather than overcrowded anti-TNF (adalimumab) or HER2 (trastuzumab) categories, Sandoz targets indications characterized by limited generic competition and favorable price retention.
-
Synergizing Manufacturing with Western Distribution: Combining Henlius’s EMA/FDA-compliant manufacturing facilities with Sandoz’s established market access networks across the U.S. and Europe delivers competitive supply chain integration.
Market Implications
-
Positive Equity Outlook for Sandoz (SIX: SDZ): Wall Street analysts (including Jefferies) view the transaction positively as a mechanism to sustain mid-term top-line biosimilar growth.
-
Validating Henlius’s Global Out-Licensing Capabilities: Securing upfront non-dilutive capital strengthens Henlius’s balance sheet, reinforcing its position as a primary Asian biomanufacturing partner for Western pharma.
-
Commercial Headwinds for Originators (Repatha®, Benlysta®, Erbitux®): Reference product manufacturers Amgen, GSK, Eli Lilly, and Merck KGaA will encounter rising biosimilar competition and pricing pressure toward the end of the decade.
Transaction Summary: Sandoz / Shanghai Henlius Biosimilar Deal
| Transaction Metric | Financial & Operational Terms | Strategic & Clinical Rationale |
| Licensee Entity | Sandoz (SIX: SDZ) | Global market leader in off-patent biologics. |
| Licensor Entity | Shanghai Henlius Biotech (HKEX: 2696) | Leading Chinese mAb discovery & manufacturing biotech. |
| Total Consideration | Up to $322 Million ($100.5M upfront + Milestones) | Framework covering up to 10 biosimilar candidates. |
| Lead Biosimilar Targets | Repatha® (evolocumab), Benlysta® (belimumab), Erbitux® (cetuximab) | Reference blockbusters delivered $6.8B in 2025 revenue. |
| Territory Rights | Henlius retains China; Sandoz holds Ex-China Rights | Integrates Asian biomanufacturing with Western channels. |
| Prior Deal (April 2025) | Biosimilar Yervoy® (ipilimumab) | $31M upfront + $270M milestone structure. |
Source: https://www.fiercepharma.com/pharma/sandoz-strikes-322m-biosimilars-deal-shanghai-henlius